McDonald’s Canada and its independent Franchisees are supporting communities impacted by the wildfires


Across Alberta, Nova Scotia, and most recently, Quebec and Ontario, communities and individuals continue to grapple with the impact of wildfires. McDonalds independent Franchisees and restaurant teams have been hard at work supporting guests and restaurant team members in these impacted communities. We also know that some of our McDonalds Canada team members have been affected by the fires. And so, as we have for over 55 years, well rally together to support our local Franchisees, their teams, and communities in times of disaster.

Here is how Franchisees and their teams responded first and fast in times of crisis.

  • Franchisee Peter MacIsaac supplied gift cards to any military personnel displaced by the fire in Halifax
  • Franchisee Dave Murray donated 140 meals in the immediate aftermath and is making a $5,000 donation to the RMHC Halifax Walk in support of displaced families
  • Franchisees Dave Murray, Mark Nelson and Bob Smith are teaming up to provide food to the Emergency Crews in Tantallon and Halifax. They have also reached out to local Fire Station in the community to drop off food as necessary and where possible
  • Franchisee Stephanie Jones is contributing food and coffee to comfort centres and donating to the Red Cross
  • Franchisee Tom Hickey has provided coffee to First Responders and local comfort centres
  • Franchisees in Northern Alberta worked together to support residents displaced by evacuation order

McDonalds Canada is proud to remain committed to its partnership with the @CanadianRedCross and will make an additional donation towards relief efforts supporting affected communities and evacuees. To support the Red Cross and find information about support available, please visit their website, here.

Japan – Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

The NDS is based on the results of the Phase III Clarity AD study and Phase IIb clinical study (Study 201), which demonstrated the lecanemab treatment showed a reduction of clinical decline in early AD. Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD)
conference, and simultaneously published in the New England Journal of Medicine, a peer-reviewed medical journal.

Lecanemab was approved under the accelerated approval pathway in the U.S. and was launched in the U.S. on January 18, 2023. The accelerated approval was based on Phase II data that demonstrated that lecanemab reduced the accumulation of Aβ plaque in the brain, a defining feature of AD, and its continued approval may be contingent upon verification of lecanemab’s clinical benefit in a confirmatory trial. The U.S. Food and Drug Administration (FDA) determined that the results of Clarity AD can serve as the confirmatory study to verify the clinical benefit of lecanemab.

In the U.S., Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on January 6, 2023. On March 3, 2023, the FDA accepted Eisai’s sBLA based on the Clarity AD clinical data, and the lecanemab application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is planning to hold an Advisory Committee to discuss this application on June 9, 2023. In Japan, Eisai submitted an application for manufacturing and marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. Priority Review was granted by the Ministry of Health, Labour and Welfare (MHLW) on January 26, 2023. Eisai utilized the PMDA’s prior assessment consultation system, with the aim of shortening the review period for lecanemab. In Europe, Eisai submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023, which was accepted on

January 26, 2023. In China, Eisai initiated submission of data for a BLA to the National Medical Products Administration (NMPA) of China in December 2022, and Priority Review was granted on February 27, 2023.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

*Protofibrils are large Aβ aggregated soluble species of 75-5000 Kd.(1)

(1) Soderberg, L., Johannesson, M., Nygren, P. et al. Lecanemab, Aducanumab, and Gantenerumab – Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics (2022). Accessed February 9, 2023

About Lecanemab

Lecanemab (Brand Name in the U.S.: LEQEMBI) is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). In the U.S., LEQEMBI was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on January 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in the U.S. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in Aβ plaques observed in patients treated with LEQEMBI. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

Please see full Prescribing Information in the United States:

Eisai has completed lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD OLE.

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. The Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has been ongoing since January 2022.

About the Collaboration between Eisai and Biogen for AD

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

About the Collaboration between Eisai and BioArctic for AD

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

About Eisai Co., Ltd.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.

For more information about Eisai, please visit (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter, LinkedIn and Facebook.

About Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

The company routinely posts information that may be important to investors on its website at Follow Biogen on social media – Twitter, LinkedIn, Facebook, YouTube.


Canada Asset Management Group Opens New Research Office in Toronto

 Canada Asset Management Group’s recent opening of a research center in Toronto’s financial district, Exchange Tower, marks a significant milestone in the company’s history. The Hong Kong-based firm, founded in 2013, has decided to retrace its roots and expand its services to offer clients the highest quality research and analysis to maintain its position as a market leader in the financial industry. The company’s Chief Trading Director, Peter Jennings, emphasized the importance of the opening of the research center, by stating that it is a pivotal and special moment in the firm’s history. The new research center will now enable Canada Asset Management Group to better serve its clients and provide them with greater opportunities through financial instruments that are in line with their investment goals.

With its prime location in Toronto’s financial district, the new research center will be able to tap into a wealth of resources and knowledge from the city’s financial community. The center will be staffed with experienced and qualified professionals who will be committed to providing clients with the most reliable and accurate analytical insights to make informed investment decisions. In summary, the launch of Canada Asset Management Group’s research center is a move towards providing its clients with the highest quality research and analysis, setting the company apart from its competitors as a leading player in the financial industry.

Canada Asset Management Group is a reputable investment management firm that has been operating in the financial industry for several years. Over time, the company has grown significantly and has now achieved a remarkable milestone of having over 8000 clients worldwide, both institutional and private. This achievement is the direct result of the company’s successful investment recommendations and strategies, which have proved to be invaluable to its clients.

Canada Asset Management Group takes a personalized approach towards investment management, tailoring its solutions to meet the specific goals and objectives of each of its clients. The firm has an experienced team of investment professionals who monitor and analyze market trends, economic indicators and individual company performance data.

This enables the company to provide clients with well-informed investment advice and recommendations that are backed by comprehensive research and analysis. Canada Asset Management Group prides itself on its ability to deliver consistent performance results that exceed its clients’ expectations. The firm’s investment philosophy is rooted in a long-term, value-based approach to investing, which emphasizes the importance of patience, discipline, and sound judgment in achieving investment success.

Canada Asset Management Group
Andre Palmovka
+852 580 31615



  • Investment

GM Canada Sales Increase 42% in Q4, and 5% for 2022


Chevrolet, Buick, GMC and Cadillac dealers delivered228,003 vehicles in 2022, including 55,724 vehicles in the fourth quarter, up 5 per cent and 42 per cent, respectively.

Our sales demonstrate the teams success increasing vehicle availability to meet strong customer demand, said Sandor Piszar, vice president, sales, service and marketing, GM Canada. As a result of those efforts, as well as working closely with our GM Canada dealers, we grew retail sales by 31 per cent this quarter, compared to Q4 2021 and more than doubled our commercial fleet sales for the calendar year. We expect to see that momentum accelerate in 2023 as we continue to rebuild dealer inventories and launch new EV and ICE vehicles across our portfolio.

2022 Sales Highlights

  • Based on strong Q4 sales, GM Canada is on track to account for 14.5 per cent of the Canadian market, up 1.8 points over 2021
  • GM Canada continues to lead in fullsize SUV sales, with a total of 19,842 sales for Chevrolet Tahoe and Suburban, GMC Yukon and Yukon XL, and Cadillac Escalade and Escalade ESV
  • GM Canada is on track to lead the market in heavy-duty truck sales, with a total of36,143 sales for Chevrolet Silverado HD and GMC Sierra HD in 2022
  • Chevrolet posted the brands best year ever for the all-electric Chevrolet Bolt and Bolt EUV, with6,372 total sales
  • Cadillac total sales increased 15 per cent as the brand delivered record retail sales for the third consecutive year

2023 New Product Launches

In 2023, GM Canada will introduce significant EV and ICE vehicle launches across GMs most popular segments.

For EVs, Canadian shipments for the CadillacLYRIQhave already begun, with the first customer deliveries expected in January. Also launching next year are the ChevroletEquinox EV, ChevroletBlazer EV, ChevroletSilverado EV, GMCSierra EV, and GMCHUMMER SUV EV.

For internal-combustion vehicles, in 2023 GM Canada will launch the all-new ChevroletTrax, the all-new ChevroletColoradoand GMCCanyon, and the updated ChevroletSilverado HDand GMCSierra HD.

About General Motors Canada

General Motors of Canada is headquartered in Oshawa, Ontario and is part of a global company that is committed to delivering safer, better and more sustainable ways for people to get around. In Canada, General Motors marketsChevrolet,Buick,GMCandCadillacvehicles through our strong Canadian network of dealers, as well asOnStarservices. More information can be found by following @GMCanada onTwitterandInstagram.

propos de GeneralMotors du Canada

GeneralMotors du Canada, dont le sige social est situ Oshawa, en Ontario, fait partie dune entreprise mondiale qui sengage offrir aux gens des solutions de transport plus scuritaires, plus efficaces et plus cologiques. Au Canada, GeneralMotors distribue les vhiculesChevrolet,Buick,GMCetCadillacpar lintermdiaire de son solide rseau de concessionnaires du Canada, en plus doffrir les servicesOnStar. Pour en savoir plus sur GMCanada, visitez abonnez-vous @GMCanada surTwitteretInstagram.

McDonald’s Canada Thanks Canadians for Joining Efforts to Help Address Food Insecurity

With help of Canadians, McDonalds Canada and its independent franchisees donate 500,000 meals to Food Banks Canada


This year, approximately 1.5 million Canadians visited a food bank.* Between Dec. 12 and Dec. 22, Canadians from coast to coast to coast who visited The Giving Page had their unique site visit count as a meal for Canadians in need, through McDonalds Canadas partnership with Food Banks Canada. With the help of these Canadians, McDonalds Canada and its independent franchisees have donated 500,000 meals to families in need.

An enormous thank you to our independent franchisees and every Canadian who joined our efforts to help address food insecurity in our communities, said Gemma Pryor, Senior Director, McDonalds Canada Impact Team. The quick response of generosity and support inspires us to keep building meaningful moments, big and small, to connect with our communities and keep showing up when they need us most.

McDonalds became part of Canadas community since the first restaurant opened in 1967. Over a million guests come through the doors of McDonalds Canadian restaurants every day, not just for the food, but because of shared community connections. This is the third year McDonalds Canada has worked with Food Banks Canada to address food insecurity during the holiday season.
McDonalds Canada will continue helping Canadians with meaningful partnerships and programs to help address food insecurity in our communities. Our ambition is to provideapproximately1 million meals every yearto Canadians in need.

We have been feeding and fostering communities across Canada for 55 years and this meaningful, ongoing partnership with Food Banks Canada is just one of the ways well continue to do that, said Pryor.

McDonalds Canada and its independent franchisees remain committed to serving its guests, employees, and the communities in which they operate. One way is by supporting programs and initiatives that care for Canadian families in need, helping reduce food insecurity and helping in times of crisis.

To find out more ways to help, please visit the Food Banks Canada website.
*Food Banks Canada Hunger Count 2022 report.

About McDonalds Canada
In 1967, Canada welcomed the first McDonalds restaurant to Richmond, British Columbia. Today, McDonalds Restaurants of Canada Limited has become part of the Canadian fabric, serving more than one million guests every day. In both franchised and corporate-owned restaurants, nearly 100,000 people are employed from coast to coast to coast, and more than 90 per cent of McDonalds 1,400 Canadian restaurants are locally owned and operated by independent franchisees. Of the almost $1 billion spent on food, more than 85 per cent is purchased from suppliers in Canada. For more information on McDonalds Canada, visit